Evidence map›Paper›PMID 38352602›Full record

ArticlebioRxiv : the preprint server for biology2024

Programmable RNA writing with trans-splicing.

Cian Schmitt-Ulms, Alisan Kayabolen, Marcos Manero-Carranza, Nathan Zhou, Keira Donnelly, Sabrina Pia Nuccio, Kazuki Kato, Hiroshi Nishimasu, Jonathan S Gootenberg, Omar O Abudayyeh

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cian Schmitt-UlmsMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Alisan KayabolenMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Marcos Manero-CarranzaMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Nathan ZhouMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Keira DonnellyMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Sabrina Pia NuccioMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Kazuki KatoDepartment of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Hiroshi NishimasuDepartment of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Jonathan S GootenbergMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-2757-2175
Omar O AbudayyehMcGovern Institute for Brain Research at MIT, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-7979-3220

Funding

Discovery and manipulation of transcription factors to restore long term stem cell repopulation in aged bone-marrowR01AG074932 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Omar O Abudayyeh, Jonathan Samuel Gootenberg · 2022 to 2026
$3.3M
Programmable gene integration and cell engineering with CRISPR-directed integrasesR01EB031957 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABUDAYYEH, OMAR O, GOOTENBERG, JONATHAN SAMUEL · 2021 to 2024
$2.4M
Developing programmable RNA writing tools with the novel RNA-guided RNA-targeting CRISPR effector Cas7-11R01GM148745 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Omar O Abudayyeh, Jonathan Samuel Gootenberg · 2023 to 2026
$1.9M
RNA targeting tools with novel specific RNA-guided RNA-targeting CRISPR effectorsR56HG011857 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABUDAYYEH, OMAR O, GOOTENBERG, JONATHAN SAMUEL · 2021 to 2021
$363k
NHGRI NIH HHS R56 HG011857NIA NIH HHS R01 AG074932NIBIB NIH HHS R01 EB031957NIGMS NIH HHS R01 GM148745
6 · The paper itself

Abstract

RNA editing offers the opportunity to introduce either stable or transient modifications to nucleic acid sequence without permanent off-target effects, but installation of arbitrary edits into the transcriptome is currently infeasible. Here, we describe Programmable RNA Editing & Cleavage for Insertion, Substitution, and Erasure (PRECISE), a versatile RNA editing method for writing RNA of arbitrary length and sequence into existing pre-mRNAs via 5' or 3' trans-splicing. In trans-splicing, an exogenous template is introduced to compete with the endogenous pre-mRNA, allowing for replacement of upstream or downstream exon sequence. Using Cas7-11 cleavage of pre-mRNAs to bias towards editing outcomes, we boost the efficiency of RNA trans-splicing by 10-100 fold, achieving editing rates between 5-50% and 85% on endogenous and reporter transcripts, respectively, while maintaining high-fidelity. We demonstrate PRECISE editing across 11 distinct endogenous transcripts of widely varying expression levels, showcasing more than 50 types of edits, including all 12 possible transversions and transitions, insertions ranging from 1 to 1,863 nucleotides, and deletions. We show high efficiency replacement of exon 4 of MECP2, addressing most mutations that drive the Rett Syndrome; editing of SHANK3 transcripts, a gene involved in Autism; and replacement of exon 1 of HTT, removing the hallmark repeat expansions of Huntington's disease. Whole transcriptome sequencing reveals the high precision of PRECISE editing and lack of off-target trans-splicing activity. Furthermore, we combine payload engineering and ribozymes for protein-free, high-efficiency trans-splicing, with demonstrated efficiency in editing HTT exon 1 via AAV delivery. We show that the high activity of PRECISE editing enables editing in non-dividing neurons and patient-derived Huntington's disease fibroblasts. PRECISE editing markedly broadens the scope of genetic editing, is straightforward to deliver over existing gene editing tools like prime editing, lacks permanent off-targets, and can enable any type of genetic edit large or small, including edits not otherwise possible with existing RNA base editors, widening the spectrum of addressable diseases.

Identifiers

PMID38352602
PMCPMC10862893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.